In:
Cancer, Wiley, Vol. 100, No. 10 ( 2004-05-15), p. 2208-2214
Abstract:
The optimal treatment for glioblastoma multiforme (GBM) in the elderly continues to be debated. In this Phase II study, the authors evaluated the efficacy and safety of temozolomide, an oral alkylating agent, as first‐line chemotherapy and exclusive treatment in elderly patients (age 〉 70 years) with newly diagnosed GBM. Nine of 29 evaluable patients (31%) achieved a partial response, and 12 of 29 patients (41%) maintained stable disease. Temozolomide also was tolerated well and was easy to administer.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v100:10
Language:
English
Publisher:
Wiley
Publication Date:
2004
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1